11 unknown. 11 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Unknown 11 |
| Phase 2 | 7 | Unknown 7 |
Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer NTQ1062 with Fulvestrant - HR Positive/HER-2 Negative Breast Cancer | Phase 1 | Unknown | Nanjing Chia-tai Tianqing Pharmaceutical | 42 | 2023-12-28 | 2024-04-23 |
| A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant, SHR-A1811 & Bevacizumab injection - HER2 Low Advanced or Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2023-04-01 | 2023-03-31 |
| Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer Dalpiciclib, Fulvestrant, Pertuzumab - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 72 | 2022-09-01 | 2024-02-26 |
| A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2) - Breast Cancer | Phase 1 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 224 | 2022-01-12 | 2022-08-17 |
| Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer CYH33, Fulvestrant, Letrozole - Advanced Breast Cancer | Phase 1 | Unknown | Haihe Biopharma Co., Ltd. | 228 | 2021-04-01 | 2021-04-23 |
| A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer TQ-B3525, Fulvestrant injection - HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 42 | 2020-07-01 | 2020-04-21 |
| A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer BPI-1178, Fulvestrant, Letrozole - Advanced Solid Tumor, HR+/HER2- Breast Cancer | Phase 1 / Phase 2 | Unknown | Beta Pharma (Suzhou) Co., Ltd. | 224 | 2020-06-15 | 2024-08-07 |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies eFT226, Sotorasib, Fulvestrant - Solid Tumor, Adult | Phase 1 / Phase 2 | Unknown | Effector Therapeutics | 30 | 2019-10-25 | 2024-05-21 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 59 | 2019-05-12 | 2023-03-07 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer G1T38, Fulvestrant - Carcinoma, Ductal, Breast, Breast Cancer | Phase 1 / Phase 2 | Unknown | G1 Therapeutics, Inc. | 102 | 2017-01-01 | 2023-02-15 |
| Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer Gedatolisib, Faslodex, Palbociclib - Breast Cancer | Phase 1 | Unknown | Hoffman Oncology | 18 | 2016-01-01 | 2022-02-09 |
Breast Neoplasms (6) · Carcinoma, Ductal, Breast (1)
Fudan University (2) · Beta Pharma (Suzhou) Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Effector Therapeutics (1) · G1 Therapeutics, Inc. (1) · Haihe Biopharma Co., Ltd. (1) · Hoffman Oncology (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1)
China (6) · United States (2) · Bulgaria (1) · Georgia (1) · Moldova (1) · United Kingdom (1)
Anthony Hoffman, MD (1) · Douglas Warner, MD (1) · Xichun Hu, PhD (1)
2016 (1)